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Nosocomiale, Hôpital Bichat-Claude Bernard, AP-HP, Paris and 6) IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité, FranceAbstractAlthough review of antibiotic therapy is recommended to optimize antibiotic use, physicians do not always perform it. This trial aimed to
evaluate the impact of a systematic postprescription review performed by antimicrobial stewardship program (ASP) infectious disease
physicians (IDP) on the quality of in-hospital antibiotic use. A multicenter, prospective, randomized, parallel-group trial using the PROBE
(Prospective Randomized Open-label Blinded Endpoint) methodology was conducted in eight surgical or medical wards of four hospitals.
Two hundred forty-six patients receiving antibiotic therapy prescribed by ward physicians for less than 24 hours were randomized to
receive either a systematic review by the ASP IDP at day 1 and days 3 to 4 (intervention group, n = 123) or no systematic review (usual
care, n = 123). The primary outcome measure was appropriateness of antimicrobial therapy, a composite score of appropriateness of
antibiotic use at days 3 to 4 and appropriate treatment duration, adjudicated by a blinded committee. Analyses were performed on an
intention-to-treat basis. In the intervention group, appropriateness of antimicrobial therapy was more frequent (55/123, 44.7% vs. 35/123,
28.5%; odds ratio 2.03, 95% conﬁdence interval 1.20–3.45). Antibiotic treatment duration was lower in the intervention group (median
(interquartile range) 7 (3–9) days vs. 10 (7–12) days; p 0.003). ASP IDP counseling to change therapy was more frequent at days 3 to 4
than at day 1 (114/123; 92.7% vs. 24/123; 19.5%, p <0.001). Clinical outcome was similar between groups. This study suggests that a
systematic postprescription antibiotic review performed at days 1 and 3 to 4 results in higher quality of antibiotic use and lower
antibiotic duration. This trial was registered at ClinicalTrials.gov (NCT01136200).
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p://dx.doi.org/10.1016/j.cmi.2014.08.015IntroductionReview of antibiotic therapy is of major importance to optimize
the use of these drugs [1–3]. Antimicrobial stewardship pro-
grams (ASP) must thus include a strong incitation to prescribers
to revaluate their prescriptions [2–6]. In France, early antibiotic
revaluation was endorsed in 2011 by the Ministry of Health as a
major component of ASP (http://www.sante.gouv.fr/). Someious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Lesprit et al. Postprescription review of antibiotics 180.e2studies assessing the impact of review by the physicians them-
selves found it was modest at best [7–9]. This suggests that an
assisted review is needed, which can be provided by ASP infec-
tious disease physicians (IDP) dedicated to this work [9–16].
However, this approach has not been properly evaluated
through a randomized multicenter trial in which criteria of
appropriateness of antimicrobial use were adjudicated by inde-
pendent investigators blinded to the randomization assignment.
We therefore undertook this trial to assess the impact of an
ASP IDP-driven review and counselling as a tool to help phy-
sicians to optimize all antibiotic prescriptions. Our main
objective was to assess whether this strategy would improve
appropriateness of antibiotic use, as assessed by a blinded
adjudication committee.MethodsStudy design and setting
The multicenter, prospective, randomized, parallel-group,
open-label ANTIBIOREF trial was conducted between May
2010 and April 2011 at four university-afﬁliated hospitals in the
Paris area. All had developed an ASP for several years, including
a senior ASP IDP devoted to this work [16–19]. The trial was
conducted in accordance with the Declaration of Helsinki and
good clinical practices, and it complied with French regulatory
requirements. It was approved by an ethics committee (Comité
de Protection des Personnes Ile de France IX, advice no. 08
030). According to the French law, patients were informed
before study inclusion of the conduct and objectives of the
research by a written document; signed informed consent was
waived, but patients had the right to opt out of participation.
This trial was registered at ClinicalTrials.gov (NCT01136200).
Wards
Two surgical or medical wards per hospital were selected as
having a high level of antibiotic consumption with the percep-
tion of ASP IDPs that antibiotic use could be improved.
Patients
All patients hospitalized in participating wards receiving antibi-
otic therapy for 24 hours were assessed for eligibility by two
independent physicians. Exclusion criteria were age <18 years,
pregnancy, antibiotic prophylaxis for less than 24 hours and
antibiotic prophylaxis for opportunistic infections.
Randomization and blinding
Patients were randomly assigned (1:1 ratio) to one of the two
groups following a computer-generated randomization scheme,
by blocks of variable and undisclosed size, stratiﬁed by hospital.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and IThe allocation sequence was concealed from the researcher
enrolling and assessing participants by using a central fax
randomization system.
Within the same 2-week period on a given ward, patients
could be randomized to intervention or control arms. In order
to control the risk of contamination of the usual care arm
(global improvement of expertise in antibiotic use within a ward
(i.e. in both trial arms) due to postprescription review and
advice from the ASP IDP experts for the intervention arm
patients), block periods of 15 days were preferred, separated
by a sufﬁciently long period (6 months) to avoid the same
residents being in the same ward at two different block periods
(in France, residents rotate every 6 months).
Intervention
The prescription guidelines were reviewed and standardized in
a common document. It was provided to participating ward
physicians 1 month before starting the study.
For patients allocated to the intervention group, the ASP IDP
visited the ward where the patient was housed at day 1 (D1)
and days 3 or 4 (D3–D4) after the ﬁrst prescription of anti-
biotic therapy during an in-hospital stay in the participating
ward (weekdays only). He provided the prescribing physician
with an oral recommendation to modify the antibiotic regimen
when deemed appropriate, and he wrote his recommendations
in the medical chart. Predeﬁned criteria for antibiotic modiﬁ-
cation proposal were those used in a previous study [16].
For patients in the usual care group, the ASP IDP performed
no systematic postprescription review. In this group, antibiotic
review was left to the discretion of the ward physicians. Advice
from the ASP IDP could be solicited by the physician if needed.
For both groups, the ward physician was the only prescriber;
he was free to follow, or not follow, the ASP IDP advice.
Compliance with ASP IDP advice included either complete or
partial adherence to recommendations and was recorded in
both groups.
Data collection
Data were collected by two independent physicians. Patients
were followed until discharge from the hospital or transfer to
another ward not participating to the trial. Sepsis and clinical
improvement were deﬁned according to previously published
criteria [20–23].
Outcomes
Because investigator blinding to group assignment was not
feasible, the main outcome criterion was adjudicated by an
expert committee blinded to trial arm allocation according to
PROBE (Prospective Randomized Open-label Blinded
Endpoint) methodology [24]. At the end of follow-up, antibioticnfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 180.e1–180.e7
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IDPs from the three other sites (which were therefore totally
independent from the one that followed the patients) using a
standardized report form. These adjudicators were not aware
of the treating physician’s notes and recommendations when
they reviewed the chart documents. They adjudicated the
appropriateness of the antibiotic regimen at the end of D1 and
D3–D4 (at the time when IDP’s recommendations were made
and could be followed). Any disagreement between the three
ASP IDP was further resolved by consensus to obtain complete
agreement.
Because many aspects of antimicrobial prescribing were
considered, we classiﬁed them into three major and six minor
criteria [25]. Major criteria included the following: (a) treatment
adequately pursued (or stopped if not indicated) at D3–D4, (b)
optimal selection of drug at D3–D4 and (c) optimal duration of
therapy (evaluated at the time of hospital discharge and deﬁned
as the duration recommended by the common guideline ±1
day). Minor criteria included (a) treatment adequately pursued
(or stopped if not indicated) at D1, (b) drug used optimal at D1,
and (c– f) modalities of administration and dosing optimal at
D1and at D3–D4.
The primary outcome measure was the appropriateness of
antimicrobial therapy, deﬁned as the presence of all three major
criteria. Secondary outcomes measures were appropriateness
of antimicrobial therapy at D1 and D3–D4; duration of therapy;
clinical improvement at day 3 and at discharge; in-hospital
mortality; and length of hospital stay. Time required (visiting
wards, contacting prescribers, issuing advice) and intervention
cost were also evaluated as follows: time spent by the IDPs was
estimated at hospital C. Antibiotic costs were estimated in all
hospitals.
Statistical analysis
The trial was designed to determine whether the ASP IDP
review was superior to usual care in terms of appropriateness
of antibiotic use. Assuming a 50% rate of appropriate pre-
scription in the control group, we hypothesized that the
intervention might result in a 70% rate of appropriate pre-
scriptions [16]. One hundred twenty-four patients per arm
would provide 90% power at a two-sided level of 0.05 to detect
such a difference.
Descriptive analyses were computed for the whole popula-
tion by randomisation group and by hospital. Categorical out-
comes were compared between groups by the chi-square or
Fisher’s test, as appropriate, and effect sizes were expressed as
odds ratio (OR) and 95% conﬁdence interval (CI). For contin-
uous outcomes, groups were compared by Student t test or
Wilcoxon test, as appropriate. Effect sizes were expressed as
differences in means and their 95% CI.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectAll analyses were conducted on an intention-to-treat basis.
Potential risk factors of the appropriateness of antimicrobial
therapy were tested by univariate logistic regression analyses.
Those associated at a level of 15% were retained to adjust for in
a multivariate logistic regression.
We added sensitivity analyses in order to test the clustering
effect of wards and hospitals using multilevel models analyses.
We tested the inﬂuence of the between-ward (levels 1; wards
nested in hospital) and between-hospital (level 2) variance on
the effect on the principal end point.ResultsStudy population
Among the 264 patients receiving antimicrobial therapy and
screened for eligibility, 246 were randomized, 123 to the
intervention group and 123 to the control group. All ran-
domized patients were followed until hospital discharge.
The clinical characteristics were similar between the two
groups (Table 1). Only 131 prescriptions (53.2%) were
microbiologically documented at D3–D4.
In the intervention group, all prescriptions were reviewed at
D1 and D3–D4 by the ASP IDP, who recommended a change
in therapy for 24 (19.5%) at D1 and 114 (92.7%) at D3–D4
(p < 0.001). Most ASP IDP recommendations (21/22, 95.4% at
D1; 106/114, 92.3% at D3–D4) were implemented by the
wards’ physicians. In contrast, the advice of the ASP IDPs were
rarely solicited by physicians in the usual care group— for ﬁve
patients (4.0%) at D1 and 19 patients (15.4%) at D3–D4.
Primary outcome
In all, 55 patients (44.7%) from the intervention group and 35
patients (28.5%) from the control group received appropriate
antimicrobial therapy (Table 2). The OR of receiving appro-
priate therapy for the intervention group vs. controls was 2.03
(95% CI 1.20–3.45). In the univariate analysis, appropriateness
differed according to the randomization group, clinical source
of infection and Charlson score (Table 3). In the multivariate
analysis, appropriateness was independently associated with the
randomization group, community acquisition and clinical source
and microbiologic documentation (Table 3). There was no
centre effect (p 0.21). No signiﬁcant clustering effect was
observed for wards or for hospital.
Secondary outcomes
Appropriateness at D1 with regard to both antimicrobial
treatment adequately pursued or stopped and optimal selection
of drug was found for half of the prescriptions (Table 2) and did
not differ signiﬁcantly between the two groups (risk ratio 0.97;ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 180.e1–180.e7
TABLE 1. Baseline patient characteristics
Characteristic
Usual care
(n [ 123)
Intervention
(n [ 123)
Sex
Male 69 (56.1) 72 (58.5)
Female 54 (43.9) 51 (41.5)
Age (years) 70 (54.5–79) 65 (55–78)
Hospital
A 17 (13.8) 14 (11.4)
B 38 (30.9) 35 (28.4)
C 50 (40.7) 53 (43.1)
D 18 (14.6) 21 (17.1)
Ward
Surgical 20 (16.3) 17 (13.8)
Medical 103 (83.7) 106 (86.2)
McCabe and Jackson classiﬁcation
Nonfatal underlying disease 56 (45.5) 61 (49.6)
Ultimately fatal underlying disease 54 (43.9) 57 (46.3)
Rapidly fatal underlying disease 13 (10.6) 5 (4.1)
Charlson score 2 (0–3) 2 (0.5–3)
Immunosuppression* 20 (16.3) 17 (13.8)
Acquisition of infection
Community acquired 64 (52.0) 57 (46.3)
Healthcare associated 12 (9.8) 19 (15.4)
Hospital acquired 47 (38.2) 47 (38.2)
Clinical source of infection
Urinary tract 39 (31.7) 29 (23.6)
Lower respiratory tract 19 (15.4) 14 (11.4)
Digestive tract 18 (14.6) 20 (16.3)
Skin and soft tissues 12 (9.7) 7 (5.7)
Other site 12 (9.7) 18 (14.6)
Colonization† 4 (3.2) 7 (5.7)
None 19 (15.4) 28 (22.7)
Severe sepsis or septic shock 4 (3.3) 5 (4.1)
Bacteremia 5 (4.1) 10 (8.1)
Microbiologic documentation
at day 3–4
61 (49.6) 70 (56.9)
Total number of pathogens
Streptococcus spp.
72 14 (19.4) 85 19 (22.3)
Staphylococcus spp. 7 (9.7) 10 (11.7)
Enterobacteriaceae 39 (54.1) 37 (43.5)
Others 12 (16.6) 19 (22.3)
Polymicrobial infection 12 (9.7) 18 (14.6)
WBC count (/mm3) 10 800
(8000–13 880)
10 650
(7300–15 780)
C-reactive protein (mg/L) 99 (36–201) 86 (17–185)
WBC, white blood cell count.
Data are shown as n (%) or median (interquartile range).
*Deﬁned by the presence of neutropenia (absolute neutrophil count <500/mm3), or
human immunodeﬁciency virus infection, or corticosteroid therapy (predni-
sone > 0.3 mg/kg per day for at least 15 days in the last 3 months) or other
immunosuppressive therapy.
†Antibiotic treatment for asymptomatic bacteriuria before surgical procedure of the
urinary tract.
CMI Lesprit et al. Postprescription review of antibiotics 180.e495% CI 0.59–1.60). In contrast, ASP IDP review led to a sig-
niﬁcant increase of the appropriateness at D3–D4 with respect
to these two criteria either combined (risk ratio: 2.19; 95% CI
1.29–3.71) or separately evaluated (antibiotic indicated or
stopped, risk ratio 2.09; 95% CI 1.03–4.22; and optimal drug,
risk ratio 2.22; 95% CI 1.20–4.11). The ASP IDP counselling
also led to a signiﬁcantly higher appropriate duration of therapy
(OR 1.75; 95% CI 1.05–2.89) and a reduction of antibiotic
exposure in patients. The difference was 3.1 days (95% CI
0.97–5.25) (Student t test p 0.003).
Clinical end points
Clinical end points did not differ signiﬁcantly between the
intervention and control groups (Table 4). Therefore, no
apparent detrimental effect was found to be associated with the
lower antibiotic exposure in patients of the intervention group.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and IOnly one patient (intervention group) died; his death was due
to an underlying event (refractory cardiogenic shock) consid-
ered to be unrelated to the intervention.
Time required and intervention cost
Median intervention time of ASP from the data from hospital C
was 40 (interquartile range (IQR) 30–50) minutes for surgical
wards and 40 (IQR 30–40) for medical wards, giving a median
cost of ASP IDP per patient of V56.6 and V67.2 in the surgical
and medical wards, respectively. Median antibiotic total cost per
patient was of V19.0 (IQR V8.0–37.8). Median time of hospi-
talization was 4.0 days (IQR 2.0–6.0 days). The cost of a public
hospital stay per day in medical or surgical wards is V781.52.
Taking into account the antibiotic total cost, length of hos-
pitalization and intervention cost of ASP IDP, we estimated the
median total cost per patient to be V1626 (IQR V90.7–3967)
in the intervention arm and V1646 (IQR V114.6–3986) in the
control arm. The difference was not signiﬁcantly different be-
tween arms (p 0.33; Wilcoxon test).
Agreement between experts of adjudication
committee
Proportion of agreement between the three assessors was
relatively high for antimicrobial treatment adequately pursued
or stopped (D1, n = 169, 68.7%; D3–D4, n = 188, 76.4%),
optimal drug at D3–D4 (n = 163, 66.2%), optimal dosing (D1,
n = 174, 70.7%; D3–D4, n = 198, 80.5%) and modalities of
administration (D1, n = 207, 84.1%; D3–D4 (n = 230, 93.5%).
In contrast, rates of agreement were lower for optimal drug at
D1 (n = 127, 51.6%) and optimal duration of therapy (n = 122,
49.6%).DiscussionThis multicenter, randomized trial including 246 patients
receiving antimicrobial therapy at admission or during their stay
in surgical and medical wards demonstrated that an ASP IDP
review results in improved quality of antibiotic use. Moreover,
this strategy markedly reduced the antibiotic exposure of pa-
tients without apparent adverse effects.
Review of antibiotic therapy aimed at increasing its appro-
priateness should cover all aspects of prescribing [5,18]. It was
implemented in some hospitals and showed efﬁcacy in
improving antimicrobial use [10–12,15,26], high compliance of
prescribers and a favourable impact on resistant bacterial
pathogens [10,12,13,27]. However, there were some limita-
tions of these studies because of their design. In this study, we
chose to include patients regardless of the antibiotic used, and
the multicenter and randomized design allowed us tonfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 180.e1–180.e7
TABLE 2. Main outcome measures
Variable Usual care (n [ 123) Intervention (n [ 123) p
Main outcome criteria* 35 (28.5) 55 (44.7) 0.008
Secondary outcome criteria
Day 1
Antibiotic indicated or adequately stopped 96 (78.0) 89 (72.4) 0.30
Optimal drug 62/96 (64.6) 61/89 (69.5) 0.57
Two criteria above 62 (50.4) 61 (49.6) 0.9
Optimal administration 87/96 (90.6) 81/89 (91.0) 0.93
Optimal dosing 78/96 (81.2) 68/89 (76.4) 0.42
Day 3–4
Antibiotic indicated or adequately stopped 97 (78.9) 109 (88.6) 0.04
Optimal drug 61/99 (61.6) 82/105 (78.1) 0.01
Two criteria above 60/120 (50.0) 81/118 (68.6) 0.003
Optimal administration 79/87 (90.8) 77/81 (95.1) 0.28
Optimal dosing 77/87 (88.5) 74/81 (91.4) 0.54
Optimal duration 55 (44.7) 72 (58.5) 0.03
Duration (days) 10 (7–16) 7 (3–14) 0.003
Data are shown as n (%) or median (interquartile range).
*Primary outcome measure was appropriateness of antimicrobial therapy deﬁned by (a) antibiotic indicated at days 3 and 4 (D3–D4) (or stopped if judged unnecessary), (b) optimal
drug at D3–D4 and (c) adequate duration according to joint guidelines.
180.e5 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIdemonstrate its effectiveness and feasibility with good internal
and external validity. Importantly, it led to lower antibiotic
exposure in patients without detrimental clinical effects, further
conﬁrming the lack of unintended clinical consequences of
these interventions [5,6].
Because ASP IDP resources are scarce in hospitals, identi-
fying determinants of efﬁcacy could help focus intervention on
speciﬁc types of patients. Apart from ASP IDP review, three
other variables (acquisition of infection, clinical source and
microbiologic documentation) were associated with appropri-
ateness of therapy [17,28]. Moreover, we were able to evaluate
the potential impact of ASP IDP counselling at two different
times of the prescription. To increase their efﬁciency, our re-
sults suggest targeting ASP IDP interventions at D3–D4 after
initiation of therapy.
The rates of appropriateness in both groups were lower
than expected. This may be explained by our main outcome
criterion: it included the appropriateness of duration of ther-
apy, which has rarely been taken into account in previous
studies [1,10,11,15]. In fact, appropriate duration was less
frequently achieved than other components of the composite
criterion. Excluding duration from the deﬁnition increases the
appropriateness in both groups (control group 28.4% to 50.0%;
intervention group 44.7% to 68.8%), and the difference
remained in favour of the intervention. Further, optimal dura-
tion was deﬁned as the duration recommended by our com-
mon guideline ±1 day. It can be argued that this was a too strict
a quality assessment of the antibiotic prescription [1,25].
Contrary to all previous studies, prescriptions were evalu-
ated by independent investigators blinded to the randomization
assignment [10,26]. Although there was a good agreement with
regard to many components of the prescription, theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectinvestigators met more difﬁculties in ﬁnding an agreement for
optimal drug and duration. Our data suggest that in further
studies, appropriateness should be reviewed by a blinded
adjudication committee.
Several limitations should be mentioned. First, our study
had an open design and involved only surgical or medical
wards. Therefore, the results ought not be extended to
intensive care units or haematology wards [29]. It should also
be noted that the study was conducted in hospitals with a long
experience of ASP. These may explain the high compliance of
physicians, which was a key component of the success of the
intervention [16]. On the other hand, we did not randomize
treating physicians but rather the patients; thus, potential
contamination between the intervention and control groups
may have diminished the measure of the effect of the
intervention.
To conclude, ASP IDP systematic review was a useful
method to improve the appropriateness of therapy in surgical
and medical wards. It also resulted in shorter antibiotic expo-
sure without negative clinical effects. Postprescription antibiotic
review is a major component of ASP and may be implemented
in many hospitals.Transparency declarationThis work was supported by a research grant from the French
Ministry of Health (PREQHOS 2008-08023). The study sponsor
(Département à la Recherche Clinique et au Dévelopement of
the Assistance Publique-Hôpitaux de Paris) had no role in the
design and interpretation of the study. All authors report no
conﬂicts of interest relevant to this article.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 180.e1–180.e7
TABLE 3. Analysis of factors associated with appropriateness of antimicrobial therapy
Characteristic
Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Sex 0.24
Female (Ref.) 1
Male 1.4 0.8–2.3
Age, per 10 years 1 0.9–1.1 0.89
Hospital 0.29
A (Ref.) 1
B 1.4 0.5–3.6
C 2.1 0.9–5.2
D 1.6 0.6–4.5
Ward 0.08 0.21
Surgical (Ref.) 1 1
Medical 1.8 0.9–3.6 1.7 0.7–4.1
McCabe classiﬁcation 0.56
Nonfatal underlying disease (Ref.) 1
Ultimately or rapidly fatal 0.9 0.5–1.4
Charlson score 0.026 0.10
<4 (Ref.) 1 1
4 0.5 0.2–0.9 0.5 0.2–1.1
Immunosuppression 0.18
No (Ref.) 1
Yes 0.6 0.3–1.3
Acquisition of infection 0.13 0.01
Community acquired (Ref.) 1 1
Health care or hospital acquired 0.7 0.4–1.1 0.4 0.4–0.8
Clinical source of infection 0.01 0.02
Urinary tract (Ref.) 1 1
Lower respiratory tract 0.4 0.2–1.2 0.6 0.2–1.8
Digestive tract 1.8 0.8–4.0 1.2 0.4–3.5
Skin and soft tissues 0.4 0.1–1.4 0.4 0.1–1.5
Other site 1.0 0.4–2.4 1.1 0.4–2.9
Prophylaxis 3.4 0.9–12.9 4.7 1.1–19.8
None 1.9 0.9–4.0 2.3 1.0–5.5
Sepsis 0.46
Yes (Ref.) 1
No 0.8 0.5–1.4
Microbiologic documentation 0.06 0.03
No (Ref.) 1 1
Yes 1.7 1.0–2.8 2.1 1.1–4.1
Randomization group 0.01 0.04
Control (Ref.) 1 1
Intervention 2.0 1.2–3.5 1.8 1.0–3.2
OR, odds ratio; CI, conﬁdence interval.
TABLE 4. Clinical outcome of included patients
Outcome Control (n [ 123) Intervention (n [ 123) p
Clinical improvement at day 3 95 (77.2) 99 (80.5) 0.53
Clinical improvement at discharge for patients discharged after day 3* 51/63 (80.9) 60/68 (88.2) 0.25
In-hospital mortality 0 (0) 1 (0.8) 1
Length of stay (days) 4 (2–6) 4 (2–6) 0.55
Data are shown as n (%) or median (interquartile range).
*Data were missing for 60 subjects in the control group and 55 in the intervention group.
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